Dan Horner takes a detailed look at the February 2021 RECOVERY tocilizumab preprint. The appraisal examines reported survival benefits alongside patient selection, incomplete follow-up, absolute versus relative effects and the uncertainties that remained behind the optimistic headlines.
The first February 2021 report of RECOVERY's tocilizumab results, written as the announcement and preprint emerged. Simon Carley and Dan Horner outline the reported benefits in hospitalised patients with hypoxia and inflammation, while flagging the need for fuller appraisal and questions about immunosuppression.
How much oxygen should critically ill patients receive? This January 2021 review of HOT-ICU examines lower versus higher oxygen targets in adults with hypoxic respiratory failure, the absence of a 90-day mortality difference and uncertainty about applying the findings to different patient groups.
A January 2021 appraisal of REMAP-CAP's early tocilizumab and sarilumab findings in critically ill patients with COVID-19. Dan Horner examines organ support and survival outcomes, strict eligibility criteria and the uncertainties that remained as the results moved rapidly into policy and public discussion.
A clinical overview of Ludwig's angina, from dental infection and deep neck anatomy to recognition and airway risk. The article reviews presentation, imaging and management challenges, with particular attention to how swelling can complicate assessment and securing the airway.
Before the fuller tocilizumab trial reports, Dan Horner examined the conflicting evidence available in December 2020. This appraisal considers biological plausibility, early REMAP-CAP announcements, adverse effects and the difficulty of discussing an experimental treatment when media coverage runs ahead of the data.
Practical perspectives on trauma care and team leadership.
Explore the series →